Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001338 · ClinicalTrials.gov registry record · Phase 2
Allopurinol Combination Study
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
NCT01001338 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 227 participants.
The verdict
NCT01001338, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
Study Summary
To compare the proportion of subjects whose serum urate (sUA) levels are \< 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG RDEA594
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001338
The ClinicalTrials.gov registry entry for NCT01001338 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01001338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001338 about?
NCT01001338 is a clinical study titled "Allopurinol Combination Study". To compare the proportion of subjects whose serum urate (sUA) levels are \< 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.
What is the current status of trial NCT01001338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2009-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01001338?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), RDEA594 (DRUG).
Who is sponsoring clinical trial NCT01001338?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.